H. Lundbeck A/S (LDBB)

Overview

H. Lundbeck A/S is a prominent biopharmaceutical company with a global presence, dedicated to the research, development, production, and distribution of pharmaceuticals aimed at treating psychiatric and neurological disorders. Founded in 1915, with its headquarters in Valby, Denmark, Lundbeck operates extensively across Europe, the United States, and other international markets. A hallmark of Lundbeck's approach is its focus on addressing complex mental health and neurological conditions, emphasizing the creation of innovative therapies that improve patient outcomes. In addition to its robust product portfolio, Lundbeck maintains strategic partnerships, including collaborations with Otsuka Pharmaceuticals Co., Ltd., and Alloy Therapeutics, Inc., to enhance its research and development capabilities in discovering novel biologic therapies.

Products and Services

• Abilify Maintena/Abilify Maintena - A key product for the treatment of schizophrenia and bipolar I disorder in adults. This medication is a cornerstone in Lundbeck's portfolio, reflecting the company's commitment to psychiatric care.

• Brintellix/Trintellix - Designed for the treatment of depressive disorders, Trintellix is a testament to Lundbeck's dedication to addressing major depressive disorders (MDD) through innovative pharmacological solutions.

• Northera - Specifically developed for treating symptomatic neurogenic orthostatic hypotension, showcasing Lundbeck's focus on neurological conditions that are often challenging to manage.

• Vyepti - Aimed at the prevention of migraine, Vyepti represents a part of Lundbeck’s efforts to combat neurological disorders through preventive measures.

• Rexulti/Rxulti - A versatile medication used to treat major depressive disorder (MDD) and schizophrenia, reflecting the dual focus of Lundbeck on both psychiatric and neurological aspects of mental health.

• Azilect - Focused on treating Parkinson's disease, Azilect is part of Lundbeck's portfolio aimed at addressing neurological disorders through targeted therapy.

• Cipralex/Lexapro - A widely recognized treatment for depression, this product underscores Lundbeck’s commitment to providing relief for patients suffering from depressive disorders.

• Ebixa - Designed to treat dementia, Ebixa is a reflection of Lundbeck’s dedication to addressing complex neurological conditions affecting cognitive function.

• Onfi - Used in the treatment of epilepsy, Onfi highlights Lundbeck’s involvement in providing solutions for seizure-related disorders.

• Sabril - Dedicated to the treatment of refractory complex partial seizures and infantile spasms, Sabril emphasizes Lundbeck’s commitment to tackling severe forms of epilepsy.

• Xenazine - For the treatment of chorea, Xenazine exemplifies Lundbeck's focus on movement disorders as part of its neurological portfolio.

• Deanxit - Addressing depression, Deanxit further showcases Lundbeck's broad approach to treating depressive and anxiety disorders.

• Cipramil - Another key product for depression and anxiety, reinforcing Lundbeck's commitment to mental health care.

• Cisordinol - A treatment for psychosis, Cisordinol rounds out Lundbeck’s comprehensive approach to mental health, addressing a range of psychiatric conditions.